Heart failure with preserved ejection fraction and obesity — evidence across compounds
Every compound the Institute assesses in heart failure with preserved ejection fraction and obesity, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in heart failure with preserved ejection fraction and obesity, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| SemaglutideGLP-1 receptor agonist (acylated, long-acting) | KCCQ clinical summary score improvement of 7.8 points versus placebo at 52 weeks | estimated difference 7.8 points (95 % CI 4.8 to 10.9) | Moderate | 2 |
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | Composite of cardiovascular death or worsening heart failure hazard ratio 0.62 | HR 0.62 (95 % CI 0.41 to 0.95); KCCQ difference 6.9 points (95 % CI 3.3 to 10.6) | Moderate | 1 |
| SS-31 (elamipretide)Mitochondria-targeted cardiolipin-binding tetrapeptide | A phase 2 trial in heart failure with preserved ejection fraction did not demonstrate benefit on the primary endpoint | negative result | Low | 1 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Incretin receptor agonists in heart failure with preserved ejection fraction and obesity — Moderate
- Semaglutide in heart failure with preserved ejection fraction and obesity: effect on the anchor outcome — Moderate
- Semaglutide in heart failure with preserved ejection fraction and obesity: tolerability and discontinuation — Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.